We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03202394
Recruitment Status : Completed
First Posted : June 28, 2017
Last Update Posted : June 25, 2020
Sponsor:
Information provided by (Responsible Party):
BioMarck Pharmaceuticals, Ltd.

Tracking Information
First Submitted Date  ICMJE June 20, 2017
First Posted Date  ICMJE June 28, 2017
Last Update Posted Date June 25, 2020
Actual Study Start Date  ICMJE August 5, 2017
Actual Primary Completion Date March 30, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 27, 2017)
Incidence of treatment-emergent adverse events [ Time Frame: 28 days ]
Assessment of frequency, type, severity, and duration of treatment-emergent Adverse Events (AE) daily during 28 day treatment period, including clinically significant laboratory abnormalities
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 27, 2017)
  • Incidence of mortality [ Time Frame: End of treatment period (28 days) and end of follow up period (180 days) ]
    Mortality will be assessed daily during treatment for 28 days and at day 180 after enrollment.
  • Number of Intensive Care Unit (ICU)-free days [ Time Frame: 28 days ]
    Number of days not in the ICU assessed daily during the 28 day treatment period.
  • Number of ventilator-free days [ Time Frame: 28 days ]
    Number of days off the ventilator assessed daily during 28 day treatment
  • Change in oxygen saturation / fraction of inspired oxygen (S/F) ratio [ Time Frame: 28 days ]
    Change in theS/F ratio assessed daily during the 28 day treatment period
  • Change in pro-inflammatory biomarkers from baseline to end of treatment [ Time Frame: pretreatment and end of treatment period (28 days) ]
    ARDS associated biomarkers will be measured in plasma
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS
Official Title  ICMJE A Phase IIa, Placebo Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO-11006 Inhalation Solution in Patients With Acute Respiratory Distress Syndrome
Brief Summary This Phase IIa pilot study is a placebo controlled, multicenter study to evaluate safety and efficacy of aerosolized BIO-11006 Inhalation Solution in ARDS patients. The subjects will be randomized 1:1 to either BIO-11006 125 mg twice daily plus standard of care or placebo plus standard of care. The treatment will continue for up to 28 days. The study will enroll up to 40 adult ARDS patients in up to eight sites within USA.
Detailed Description

This is a randomized, double blind, placebo controlled, parallel-group Phase IIa pilot study of aerosolized BIO 11006 in patients with sepsis-induced acute respiratory distress syndrome (ARDS). All patients enrolled in the study will be ventilated. To be eligible for enrollment, patients must be adults who have sepsis-induced ARDS within 48 hours prior to enrollment, require intubation, and exhibit bilateral infiltrates consistent with pulmonary edema on the frontal chest radiograph within 48 hours of enrollment. Patients will be randomized in a 1:1 ratio to either BIO-11006 125 mg twice daily (BID) plus standard of care ventilation or placebo (half normal saline [HNS]) BID plus standard of care ventilation. Patients randomized to receive BIO-11006 or placebo will start dosing at the time of ventilation and continue for up to 28 days or length of ventilation (if shorter). Patients in both groups will receive best available standard of care treatment, including low-volume mechanical ventilation as indicated by clinical judgment and patient response. The maximum duration of treatment will be 30 days.

The primary objective of this study is to evaluate the safety and efficacy of aerosolized BIO-11006 at a dose of 125 mg BID in ventilated patients who have ARDS. Safety is the primary endpoint in this study and will be monitored by adverse event reporting, oxygenation, mortality, vital signs, ventilator-free days, and ICU-free days.

This study will enroll up to 40 adult patients with ARDS induced by sepsis who first met the Berlin Criteria for ARDS within 48 hours of enrollment, and who require intubation and exhibit bilateral opacities consistent with pulmonary edema on frontal chest radiograph within 48 hours of enrollment.

BIO 11006 Inhalation Solution drug product is formulated at a dosage strength of 41.67 mg/mL (125 mg/3 mL) as an aqueous solution containing sodium chloride and is intended for aerosol administration by the "Aeroneb Pro®" nebulizer to patients randomized to active treatment.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Patients will be randomized in a 1:1 ratio to either BIO 11006 125 mg twice daily (intervention) plus standard of care ventilation or placebo BID plus standard of care ventilation. Patients randomized to receive BIO 11006 or placebo will start dosing at the time of ventilation and continue for up to 30 days or length of ventilation (if shorter).
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Respiratory Distress Syndrome, Adult
Intervention  ICMJE
  • Drug: BIO-11006
    Intervention involves aerosolized delivery of either the active drug or placebo by the "Aeroneb Pro nebulizer".
  • Drug: Placebo
    Intervention involves aerosolized delivery of either the active drug or placebo by the "Aeroneb Pro nebulizer".
    Other Name: Half Normal saline
Study Arms  ICMJE
  • Active Comparator: Active intervention
    Patients will be randomized in a 1:1 ratio to either aerosolized BIO-11006 (125mg in 3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or placebo.
    Intervention: Drug: BIO-11006
  • Placebo Comparator: Placebo intervention
    Patients will be randomized in a 1:1 ratio to either aerosolized placebo (3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or active drug.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 23, 2020)
38
Original Estimated Enrollment  ICMJE
 (submitted: June 27, 2017)
60
Actual Study Completion Date  ICMJE June 15, 2020
Actual Primary Completion Date March 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Has provided (or relative has) written informed consent and authorization for use and disclosure of protected health information
  2. Has a clinical diagnosis of sepsis or septic shock defined as:

    • Known or suspected infection
    • Systemic inflammatory response syndrome (SIRS), defined as meeting at least 2 of the following 3 criteria for a systemic inflammatory response:

      • White blood cell count >12,000 or <4,000 or >10% band forms
      • Body temperature >38°C (any route) or <36°C (by core temperatures only: indwelling catheter, esophageal, rectal)
      • Heart rate >90 beats/min or receiving medications that slow heart rate or pace rhythm
  3. Enrollment must occur within 48 hours of first meeting ARDS criteria per the Berlin definition of ARDS (ARDS Task Force 2012) and no more than 72 hours from the initiation of mechanical ventilation. (The bilateral opacities, respiratory failure, and decreased P/F ratio must all be present within a 24 hour time period of one another.):

    • Lung injury of acute onset, within 1 week of an apparent clinical insult, with progression of respiratory symptoms
    • Bilateral opacities on chest imaging not fully explained by effusions, lobar/lung collapse, or nodules.
    • Respiratory failure not fully explained by cardiac failure or fluid overload. (Need objective assessment (e.g. echocardiography) to exclude hydrostatic edema if no risk factor present.)
    • Decreased arterial partial pressure of oxygen (PaO2)/ fraction of inspired oxygen (FIO2) ratio while on a minimum Positive End Expiratory Pressure (PEEP) of 5 cm water (H2O):

      • Moderate ARDS: 101 to 200 mmHg (≤ 26.6 kPa)
      • Severe ARDS: ≤ 100 mmHg (≤ 13.3 kPa)

Exclusion Criteria:

  1. Age < 18 years or >75 years old
  2. Greater than 48 hours since first meeting ARDS criteria per the Berlin definition of ARDS
  3. Pregnant or breastfeeding (negative pregnancy test required prior to randomization for female patients of childbearing potential.)
  4. Prisoner
  5. Any other irreversible disease or condition for which 6 month mortality is estimated to be > 50%
  6. Moderate to severe liver failure (Child Pugh Score > 12)
  7. Severe chronic respiratory disease with a PaCO2 > 50 mmHg or the use of home oxygen
  8. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).
  9. Major trauma in the prior 5 days
  10. Lung transplant patient
  11. No consent/inability to obtain consent
  12. Moribund patient not expected to survive 24 hours
  13. World Health Organization (WHO) Functional Class III or IV pulmonary hypertension
  14. No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol
  15. Currently receiving extracorporeal life support or high frequency oscillatory ventilation
  16. Known hypersensitivity to BIO 11006
  17. Burn victims >20% Total Body Surface Area (TBSA) or with known airway inhalation injury
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03202394
Other Study ID Numbers  ICMJE BIM-CL-005
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party BioMarck Pharmaceuticals, Ltd.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE BioMarck Pharmaceuticals, Ltd.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Brian Dickson, MD Biomarck Pharmaceuticals
PRS Account BioMarck Pharmaceuticals, Ltd.
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP